Study links vinorelbine after surgery to longer survival in dogs

A new retrospective multicenter study in the Journal of Small Animal Practice suggests that dogs with grade II and III pulmonary carcinoma may gain a survival advantage from vinorelbine-based adjuvant chemotherapy after surgery. According to the study abstract, dogs treated with vinorelbine-based postoperative therapy had longer progression-free survival and overall survival than dogs managed with surgical resection alone. That’s a meaningful signal in a disease where surgery is the mainstay of care, but the value of postoperative chemotherapy has remained unsettled. (pubmed.ncbi.nlm.nih.gov)

That uncertainty is what makes this paper important. Previous canine pulmonary carcinoma studies have shown that outcome after lung lobectomy is heavily influenced by tumor biology and stage, including tumor size, lymph node metastasis, incomplete excision, and histologic grade. A 2020 retrospective study of surgically excised primary pulmonary carcinomas found no statistically significant benefit from adjuvant chemotherapy overall, while a 2025 JSAP study of 89 dogs concluded that more work is still needed to clarify the role of adjuvant chemotherapy in clinically aggressive lung cancer. (pubmed.ncbi.nlm.nih.gov)

Against that backdrop, the new study is more targeted. Rather than pooling all comers, it focuses specifically on grade II and III pulmonary carcinoma, a higher-risk population where micrometastatic disease is a more pressing concern. That narrower framing may help explain why the authors detected a difference where broader retrospective datasets did not. The source abstract says the comparison was between vinorelbine-based adjuvant treatment after surgical resection and surgery alone, and that both progression-free and overall survival were longer in the adjuvant group. Because only the abstract is currently available in our source material, key details such as case numbers, staging breakdown, margin status, exact vinorelbine protocol, and adverse-event rates will matter when clinicians interpret how practice-changing the findings really are. (pubmed.ncbi.nlm.nih.gov)

Vinorelbine is a logical drug to study in this setting. Prior veterinary literature has described it as a semisynthetic vinca alkaloid with high lung tissue concentrations and a relatively low toxicity profile in dogs. In a 2015 JAVMA retrospective series of 58 dogs with various malignancies, including pulmonary carcinoma, vinorelbine showed antitumor activity, although benefit in the adjuvant subgroup was harder to quantify. More recently, a 2023 study of dogs with stage IV primary pulmonary carcinoma reported activity for vinorelbine as first-line treatment in advanced disease. Taken together, those reports have supported vinorelbine’s biologic plausibility, even if postoperative evidence has lagged behind. (pubmed.ncbi.nlm.nih.gov)

There does appear to be a broader trend in the literature toward refining which lung cancer patients are most likely to benefit from added therapy. A 2023 study in small-breed dogs reinforced tumor size as an important prognostic factor after resection, and the 2025 JSAP lung lobectomy paper noted that adjuvant treatment was generally reserved for dogs with metastatic disease or aggressive histopathologic features. In other words, clinicians are already risk-stratifying these cases in practice, even without a universally accepted postoperative standard. This new study fits that pattern by focusing on dogs whose grade alone places them in a more concerning category. (pubmed.ncbi.nlm.nih.gov)

Why it matters: For veterinary professionals, the practical takeaway is that this paper may strengthen the case for discussing vinorelbine-based adjuvant therapy more proactively with pet parents of dogs that have resected grade II or III pulmonary carcinoma. It doesn’t erase the limitations of retrospective data, including selection bias and institutional variation, but it may help narrow the gap between biologic rationale and clinical decision-making. In referral and specialty settings, that could mean more consistent postoperative oncology consultations for high-grade cases, more attention to standardized staging and nodal assessment, and more nuanced conversations about expected benefit versus treatment burden. (pubmed.ncbi.nlm.nih.gov)

There’s also a translational angle worth noting, cautiously. In human non-small cell lung cancer, vinorelbine has a long history in adjuvant protocols after complete resection, particularly in stage II and III disease. That doesn’t make the canine data directly comparable, but it does reinforce why vinorelbine has remained of interest in veterinary lung oncology and why evidence of benefit in a higher-risk postoperative canine subset will draw attention. This is an inference based on the parallel treatment logic, not proof of equivalence across species. (pubmed.ncbi.nlm.nih.gov)

What to watch: The next step is the full paper. Veterinary oncologists will want the exact survival medians, hazard estimates if reported, toxicity data, completion rates, and subgroup analyses by stage, nodal status, and margin status before deciding how broadly to apply the findings. If those details hold up, vinorelbine-based adjuvant therapy could become a more evidence-backed recommendation for selected dogs after lung lobectomy, rather than a case-by-case option used mainly on clinical instinct. (pubmed.ncbi.nlm.nih.gov)